VTGN (Vistagen Therapeutics) Tangible Book per Share : $2.43 (As of Mar. 2025)

Vistagen Therapeutics Tangible Book per Share Chart

Vistagen Therapeutics Annual Data
	Trend	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24	Mar25
Tangible Book per Share		Get a 7-Day Free Trial					15.28	9.40	1.65	4.23	2.43

Vistagen Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Tangible Book per Share	Get a 7-Day Free Trial															4.23	3.87	3.44	2.87	2.43

Competitive Comparison of Vistagen Therapeutics's Tangible Book per Share

For the Biotechnology subindustry, Vistagen Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vistagen Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Vistagen Therapeutics's Price-to-Tangible-Book falls into.

Vistagen Therapeutics Tangible Book per Share Calculation

Vistagen Therapeutics's Tangible Book Value Per Share for the fiscal year that ended in Mar. 2025 is calculated as

Vistagen Therapeutics's Tangible Book Value Per Share for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.

Vistagen Therapeutics  (NAS:VTGN) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Vistagen Therapeutics Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Vistagen Therapeutics's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Vistagen Therapeutics Business Description